Pancreatic Cancer Drug Doubles Patient Survival Time in Landmark Trial

Pancreatic cancer kills 78% of the people it strikes within five years [1]. For decades, the disease has resisted every therapeutic advance that transformed outcomes in breast cancer, lung cancer, and melanoma. On May 31, 2026, at the plenary session of the American Society of Clinical Oncology annual meeting in Chicago, a Phase 3 trial reported results that no one in the field had seen before: a single oral pill nearly doubled overall survival compared to standard chemotherapy in previously treated patients [2].

The drug is daraxonrasib, formerly known as RMC-6236, made by Revolution Medicines. The trial is RASolute 302. The numbers — 13.2 months median overall survival versus 6.7 months — represent the largest survival improvement ever demonstrated in a randomized trial for metastatic pancreatic ductal adenocarcinoma [3]. The results were simultaneously published in the New England Journal of Medicine [4].

But behind the headlines, hard questions remain about who can access this drug, what it costs, how the trial was designed, and whether the "doubling" claim holds up under scrutiny.

The Disease: Why Pancreatic Cancer Is Different

An estimated 67,530 Americans will be diagnosed with pancreatic cancer in 2026, and 52,740 will die from it [1]. That ratio — roughly four deaths for every five diagnoses — makes it the deadliest of all major cancers. It is now the third-leading cause of cancer death in the United States and is projected to become the second [1].

Source: American Cancer Society

Data as of Jan 1, 2026CSV

The five-year survival rate has improved from 4.6% in 2000 to approximately 13% in 2025, but this remains far below the gains seen in other cancers [5]. For patients diagnosed with distant (metastatic) disease — the population studied in RASolute 302 — five-year survival is just 3% [5].

Source: American Cancer Society / SEER

Data as of Jan 1, 2026CSV

What makes pancreatic cancer so resistant is biological. The tumors are surrounded by a dense stromal barrier — a thick wall of connective tissue that blocks drugs from reaching cancer cells. The tumor microenvironment is immunosuppressive, rendering checkpoint inhibitors largely ineffective. And more than 90% of pancreatic adenocarcinomas are driven by mutations in the KRAS gene, which for decades was considered "undruggable" [6][7].

What Daraxonrasib Does

Daraxonrasib is a first-in-class oral multi-selective RAS(ON) inhibitor. It works as a molecular glue: the drug pairs with a naturally occurring protein called cyclophilin A to directly block the activated form of the RAS protein, shutting down the oncogenic signaling that drives tumor growth [3][6].

This approach differs from earlier KRAS-targeted drugs like sotorasib and adagrasib, which only work against the specific G12C mutation — a variant found in roughly 1-2% of pancreatic cancers. Daraxonrasib is "multi-selective," meaning it can inhibit multiple KRAS variants, including the G12D, G12V, and G12R mutations that collectively account for the vast majority of KRAS-driven pancreatic tumors [6][7].

The scientific interest in this mechanism has been building rapidly. Research publications on pancreatic cancer and KRAS inhibitors peaked at over 7,300 papers in 2023 and have remained at elevated levels since [8].

Source: OpenAlex

Data as of Jan 1, 2026CSV

The Trial: What RASolute 302 Found

RASolute 302 enrolled 500 patients across North America, Europe, and Asia. All had metastatic pancreatic ductal adenocarcinoma that had progressed after at least one line of chemotherapy. Patients were randomized to receive either daraxonrasib (300 mg orally, once daily) or the investigator's choice of second-line chemotherapy [4].

Source: NEJM / RASolute 302 Trial

Data as of May 31, 2026CSV

The primary endpoint was overall survival, not the sometimes more favorable metric of progression-free survival. This is a meaningful distinction. The trial delivered on both:

• Median overall survival: 13.2 months (daraxonrasib) vs. 6.7 months (chemotherapy) [4]
• Hazard ratio for death: 0.40, representing a 60% reduction in the risk of death [3]
• Median progression-free survival: 7.2 months vs. 3.6 months [4]
• Objective response rate: 31.6% vs. 11.2% [3]

Among patients with confirmed RAS G12 mutations, results were even stronger: 8.5 months progression-free survival and a 33.2% objective response rate [4].

The trial's principal investigator was Dr. Brian M. Wolpin, professor of medicine at Harvard Medical School and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute. The trial was funded by Revolution Medicines [2][3].

"This really feels like a watershed moment," Wolpin said at the ASCO presentation. "It's going to shift how we think about treatment" [9].

Who Was — and Wasn't — in the Trial

The trial enrolled adults with metastatic PDAC who had already received one line of chemotherapy and had adequate organ function and performance status [4]. This is a critical detail. First-line patients — those who have not yet tried chemotherapy — were excluded. So were patients too sick to meet standard performance status thresholds, a common scenario in a disease that deteriorates quickly.

Of the roughly 67,530 Americans diagnosed with pancreatic cancer each year, approximately 55% present with metastatic disease [1][5]. But only a fraction of those receive and then progress through first-line chemotherapy in good enough condition to qualify for a second-line trial. Estimates from oncology literature suggest that 30-50% of metastatic patients receive second-line treatment [10]. That narrows the immediately eligible US population to roughly 11,000-18,500 patients per year — a meaningful number, but far from the full burden of disease.

A separate Phase 3 trial, RASolute 303, is now testing daraxonrasib in the first-line setting — as monotherapy, in combination with chemotherapy, or against chemotherapy alone [6]. Those results, expected in 2027-2028, will determine whether the drug's benefit extends to the broader patient population.

Side Effects and Quality of Life

One of the strongest arguments for daraxonrasib is that patients appear to feel better on it than on chemotherapy — and the data supports this.

Grade 3 or higher treatment-related adverse events occurred in 43.6% of daraxonrasib patients versus 57.5% on chemotherapy [4]. Only 1.2% of patients discontinued daraxonrasib due to side effects, compared to 11.2% on chemotherapy [3].

The drug's signature side effect is rash, affecting approximately 90% of patients. About 15% experienced severe rash requiring temporary treatment pauses, but the condition was manageable with antibiotic creams and sun protection [9][11]. Other common side effects included diarrhea (~50%), mouth sores, and gastrointestinal inflammation [4]. Notably absent were the chemotherapy hallmarks of neutropenia (dangerously low white blood cell counts), peripheral neuropathy, and severe fatigue.

Patient-reported outcomes told a parallel story. The median time to deterioration in pain was 9.2 months on daraxonrasib versus 3.8 months on chemotherapy. Time to deterioration in global health status was 5.7 months versus 2.6 months [3][4]. Both differences were statistically significant.

"Much more tolerable than chemo," Wolpin stated. "Most patients greatly prefer the ability to take a pill every day" [9].

Former U.S. Senator Ben Sasse, 54, diagnosed with Stage 4 pancreatic cancer in December 2025, reported a 76% reduction in tumor volume after four months on daraxonrasib through the expanded access program. On CBS 60 Minutes, he called it "a miracle drug," though he described the rash as "nuclear" [12].

The Cost Question

Revolution Medicines has not disclosed pricing for daraxonrasib [6]. This is standard for drugs that have not yet received regulatory approval, but it creates a significant blind spot in assessing the drug's real-world impact.

Context from comparable targeted oral oncology drugs suggests a price range in the tens of thousands of dollars per month. Sotorasib (Lumakras), the first approved KRAS G12C inhibitor, was priced at approximately $17,900 per month at launch [13]. Standard pancreatic cancer chemotherapy regimens cost between $40,000 and $200,000 per year, with FOLFIRINOX at roughly $83,835 annually and gemcitabine/nab-paclitaxel at approximately $54,842 [10].

Wall Street analysts project peak annual sales for daraxonrasib exceeding $7 billion [6]. Revolution Medicines' market capitalization stood at approximately $29 billion as of spring 2026, despite being a pre-revenue company. The company doubled a planned public stock offering to $2 billion following the trial results [14].

For health technology assessment bodies, the relevant metric is cost per quality-adjusted life year (QALY). The UK's National Institute for Health and Care Excellence (NICE) generally considers treatments cost-effective below £30,000 ($38,000) per QALY [15]. In the US, the Institute for Clinical and Economic Review (ICER) uses thresholds of $50,000-$150,000 per QALY [15]. With a survival gain of 6.5 months and demonstrated quality-of-life improvements, the cost-effectiveness calculation will depend heavily on the final price point. At $15,000 per month — a conservative estimate for a drug in this class — the annual cost would exceed $180,000, placing it above typical ICER thresholds unless discounted heavily by payers.

How This Compares to Other "Landmark" Approvals

The 6.5-month improvement in median overall survival is striking in context. Recent drugs that generated comparable excitement in oncology delivered smaller absolute gains in their pivotal trials:

• Pembrolizumab (Keytruda) in non-small cell lung cancer: approximately 4-6 months median OS improvement in first-line monotherapy trials [16].
• Osimertinib (Tagrisso) in EGFR-mutant lung cancer: approximately 6.8-month OS improvement over prior-generation inhibitors [16].
• Olaparib (Lynparza) in BRCA-mutant ovarian cancer: significant PFS benefit but mature OS data took years to confirm [16].

For pancreatic cancer specifically, the bar has been far lower. The MPACT trial of nab-paclitaxel plus gemcitabine — the last treatment to meaningfully change the standard of care — improved median overall survival by just 1.8 months (8.5 vs. 6.7 months) when it was reported in 2013 [10]. Daraxonrasib's hazard ratio of 0.40 is roughly twice as favorable as what MPACT showed [3].

"For that to exceed one year is really extraordinary," said Dr. Emil Lou of the University of Minnesota [17]. "This is a big deal. This drug is the most exciting thing in pancreas cancer in over a decade," said Dr. Reza Nazemzadeh of Atrium Health Levine Cancer [18].

Reasons for Caution

Despite the strong results, several structural features of the trial warrant attention.

Open-label design. RASolute 302 was not blinded — patients and doctors knew which treatment they were receiving [4]. While this is common in oncology trials where placebo-controlled designs raise ethical concerns (especially against active chemotherapy), it can introduce bias in subjective endpoints, including patient-reported outcomes. The overall survival endpoint, however, is objective and not subject to this bias.

Second-line setting only. The current data applies to patients who have already progressed on chemotherapy. Whether daraxonrasib works as well — or better — in the first-line setting remains unknown pending RASolute 303 results [6].

Single-agent vs. combination. Many oncology drugs show strong single-agent results in early trials but are ultimately used in combination regimens. The interaction between daraxonrasib and standard chemotherapy agents is still being studied [6].

Durability. A 13.2-month median overall survival is a dramatic improvement, but it is still a median. Half of patients lived less than 13.2 months. Long-term follow-up data — particularly two-year and three-year survival rates — have not yet been reported [4].

Biomarker selection. While the trial enrolled all-comers with PDAC (since >90% have KRAS mutations), the enhanced results in the RAS G12 mutation-positive subgroup raise the question of whether the "doubling" is uniform across the trial population or partly driven by the most responsive molecular subtype [4]. The overall population result of 13.2 vs. 6.7 months is robust, but granular subgroup analyses have not been fully published.

The Access Gap

The FDA granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation, and approved an expanded access program within two days of Revolution Medicines' request [19][20]. FDA Commissioner Marty Makary stated the decision "reflects the FDA's strong commitment to facilitate early access to therapies for serious and life-threatening conditions" [19].

But FDA approval of the drug itself — through a New Drug Application — has not yet occurred. Revolution Medicines has indicated it intends to file but has not specified a timeline [6]. Even with priority review, the NDA process typically takes 6-10 months from submission.

In Europe, the European Medicines Agency granted orphan drug designation in April 2026, but no marketing authorization application has been filed. Access for European patients is unlikely before late 2027 at the earliest [21].

For low- and middle-income countries, the timeline is far longer. Even existing pancreatic cancer chemotherapy regimens — drugs that have been generic for years — remain inaccessible in much of sub-Saharan Africa, South Asia, and Southeast Asia due to infrastructure, cost, and diagnostic capacity constraints [22]. A novel oral targeted therapy with a premium price tag faces all of those barriers and more. The World Health Organization does not include any pancreatic cancer-specific treatments on its Model List of Essential Medicines [22].

"For all the years that I've been treating and developing new therapies for pancreatic cancer, it's still a death sentence," said Dr. Elizabeth Jaffee of Johns Hopkins, contextualizing both the significance and the limitations of the advance [17].

What Comes Next

Three developments will determine whether daraxonrasib transforms outcomes for the broader pancreatic cancer population or remains a significant but bounded advance:

First-line trial results. RASolute 303, testing daraxonrasib as initial treatment rather than after chemotherapy failure, will reveal whether the drug can extend survival when patients are in better overall health. If the benefit holds or improves in the first-line setting, the eligible patient population expands dramatically [6].

Pricing and payer decisions. Revolution Medicines' pricing strategy will determine real-world access in the US and influence health technology assessments globally. A price that falls within ICER's cost-effectiveness thresholds could accelerate coverage; one that exceeds them will face significant pushback [15].

Combination strategies. Trials combining daraxonrasib with immunotherapy, chemotherapy, or other targeted agents could further improve outcomes — or reveal new toxicity profiles [6].

For now, the RASolute 302 results represent an unambiguous step forward for a disease that has resisted progress for decades. Whether that step reaches the patients who need it most — and at a price societies can sustain — is the question that matters next.